-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-02-10
GRI:NSD-GRI Bio Inc. (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.481Change
+0.00 (+0.42)%Market Cap
N/AVolume
0.15MAnalyst Target
N/A![](https://ducovest.com/tools/assets/assets/images/analyst-meter.png)
N/A
Verdict
Values as of: 2025-02-10
COMMON STOCK | Biotechnology |
Last Closing
USD 0.481Change
+0.00 (+0.42)%Market Cap
N/AVolume
0.15MAnalyst Target
N/AN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
+0.65 (+0.14%) |
USD 118.90B |
REGN | Regeneron Pharmaceuticals Inc |
-19.64 (-2.77%) |
USD 73.95B |
ARGX | argenx NV ADR |
-0.19 (-0.03%) |
USD 40.41B |
ALNY | Alnylam Pharmaceuticals Inc |
-2.13 (-0.77%) |
USD 34.99B |
ONC | BeiGene, Ltd. |
-3.83 (-1.71%) |
USD 25.62B |
RPRX | Royalty Pharma Plc |
-0.01 (-0.03%) |
USD 18.12B |
SMMT | Summit Therapeutics PLC |
+0.39 (+1.94%) |
USD 17.52B |
UTHR | United Therapeutics Corporatio.. |
-2.07 (-0.60%) |
USD 15.68B |
INCY | Incyte Corporation |
-5.83 (-7.86%) |
USD 14.29B |
INSM | Insmed Inc |
-1.83 (-2.29%) |
USD 13.70B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
IUKP:SW | iShares UK Property UCITS.. | 3.33 % | 0.00 % |
+0.04 (+1.11%) |
USD 0.59B |
UKPH:XETRA | iShares UK Property UCITS.. | 3.23 % | 0.00 % |
+0.04 (+1.11%) |
N/A |
IUKP:LSE | iShares UK Property UCITS | 0.00 % | 0.00 % |
+4.58 (+1.11%) |
USD 0.59B |
UKRE:LSE | iShares MSCI Target UK Re.. | 0.00 % | 0.00 % |
+4.05 (+1.11%) |
USD 0.10B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -41.94% | 8% | B- | 5% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -41.94% | 8% | B- | 5% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -96.94% | 3% | F | 2% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -96.94% | 3% | F | 2% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -100.00% | N/A | F | N/A | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -100.00% | N/A | F | N/A | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -37.79% | 7% | C- | 3% | F | ||
Dividend Return | -37.79% | 7% | C- | 3% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 47.30% | 67% | D+ | 40% | F | ||
Risk Adjusted Return | -79.90% | 11% | F | 7% | C- | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This stock has shown below median earnings growth in the previous 5 years compared to its sector